Sarepta Therapeutics (SRPT) News Today $110.86 +4.24 (+3.98%) (As of 11/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Sarepta Therapeutics (NASDAQ:SRPT) Rating Lowered to "Hold" at StockNews.comStockNews.com downgraded Sarepta Therapeutics from a "buy" rating to a "hold" rating in a research note on Wednesday.November 20 at 3:23 AM | marketbeat.comBraun Stacey Associates Inc. Acquires 4,827 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)Braun Stacey Associates Inc. lifted its position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 4.9% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 103,012 shares of the biotechnology company's stock after purchasing an additionNovember 18 at 7:21 AM | marketbeat.comThrivent Financial for Lutherans Has $78.04 Million Holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)Thrivent Financial for Lutherans trimmed its holdings in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 3.1% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 624,888 shares of the biotNovember 18 at 5:40 AM | marketbeat.comSarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Sold by Aigen Investment Management LPAigen Investment Management LP lessened its position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 81.4% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 1,823 shares of the biotechnology company's stock after selNovember 17, 2024 | marketbeat.comSarepta Therapeutics, Inc. (NASDAQ:SRPT) Given Average Rating of "Buy" by BrokeragesNovember 17, 2024 | americanbankingnews.comMizuho Markets Americas LLC Purchases 72,765 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)Mizuho Markets Americas LLC grew its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 22.3% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 399,065 shares of the biotechnology company's stockNovember 16, 2024 | marketbeat.comSarepta Therapeutics, Inc. (SRPT): Among 12 High Growth Large Cap Stocks to Buy NowNovember 15, 2024 | msn.comSarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Acquired by Simplify Asset Management Inc.Simplify Asset Management Inc. raised its stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 84.6% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 193,010 shares of the biotechnology company'sNovember 15, 2024 | marketbeat.comJanus Henderson Group PLC's Strategic Acquisition in Sarepta Therapeutics IncNovember 14, 2024 | gurufocus.comWhy Sarepta Therapeutics' (NASDAQ:SRPT) Earnings Are Weaker Than They SeemNovember 14, 2024 | finance.yahoo.comAssetmark Inc. Has $4.87 Million Stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)Assetmark Inc. raised its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 230.6% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 39,025 shares of the biotechnology company'November 12, 2024 | marketbeat.comPrincipal Financial Group Inc. Decreases Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)Principal Financial Group Inc. decreased its position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 26.4% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 267,037 shares of the biotechnology comNovember 12, 2024 | marketbeat.comSarepta Therapeutics, Inc. (NASDAQ:SRPT) Receives Consensus Recommendation of "Buy" from AnalystsShares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Get Free Report) have been given an average recommendation of "Buy" by the twenty-two brokerages that are presently covering the stock, MarketBeat reports. One analyst has rated the stock with a hold rating, twenty have issued a buy rating and oNovember 12, 2024 | marketbeat.comSarepta recent weakness brings buying opportunity, says JPMorganNovember 11, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Sarepta Therapeutics (SRPT) and DocGo (DCGO)November 11, 2024 | markets.businessinsider.comStrong Financial Performance and Strategic Advancements Support Sarepta Therapeutics’ Buy RatingNovember 10, 2024 | markets.businessinsider.comSarepta Therapeutics Inc (SRPT)November 9, 2024 | uk.investing.comFiera Capital Corp Decreases Holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)Fiera Capital Corp lowered its holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 5.9% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 359,996 shares of the biotechnology company's stock after selling 22,649 shares duringNovember 8, 2024 | marketbeat.comEvercore ISI Keeps Their Buy Rating on Sarepta Therapeutics (SRPT)November 8, 2024 | markets.businessinsider.comSarepta Therapeutics: Strong Elevidys Sales Drive Upward Revision and Buy RatingNovember 8, 2024 | markets.businessinsider.comStrong Q3 Performance and Future Growth Prospects Justify Buy Rating on Sarepta TherapeuticsNovember 8, 2024 | markets.businessinsider.comCantor Fitzgerald Upgrades Sarepta Therapeutics (SRPT)November 8, 2024 | msn.comSarepta Therapeutics (NASDAQ:SRPT) Stock Price Down 7.6% After Analyst DowngradeSarepta Therapeutics (NASDAQ:SRPT) Shares Down 7.6% After Analyst DowngradeNovember 7, 2024 | marketbeat.comSarepta Therapeutics (NASDAQ:SRPT) Price Target Raised to $150.00Guggenheim lifted their target price on shares of Sarepta Therapeutics from $148.00 to $150.00 and gave the stock a "buy" rating in a research note on Thursday.November 7, 2024 | marketbeat.comRobert W. Baird Lowers Sarepta Therapeutics (NASDAQ:SRPT) Price Target to $193.00Robert W. Baird cut their target price on Sarepta Therapeutics from $200.00 to $193.00 and set an "outperform" rating for the company in a research note on Thursday.November 7, 2024 | marketbeat.comEvercore ISI Issues Pessimistic Forecast for Sarepta Therapeutics (NASDAQ:SRPT) Stock PriceEvercore ISI cut their price target on shares of Sarepta Therapeutics from $179.00 to $170.00 and set an "outperform" rating on the stock in a research note on Thursday.November 7, 2024 | marketbeat.comSarepta Therapeutics' (SRPT) "Buy" Rating Reiterated at Needham & Company LLCNeedham & Company LLC reissued a "buy" rating and set a $205.00 price objective on shares of Sarepta Therapeutics in a report on Thursday.November 7, 2024 | marketbeat.comSarepta Therapeutics (NASDAQ:SRPT) Rating Increased to Overweight at Cantor FitzgeraldCantor Fitzgerald raised shares of Sarepta Therapeutics from a "neutral" rating to an "overweight" rating and lifted their price objective for the company from $152.00 to $167.00 in a research note on Thursday.November 7, 2024 | marketbeat.comVan ECK Associates Corp Has $8.85 Million Stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)Van ECK Associates Corp reduced its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 18.0% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 68,176 shares of the biotechnology company's sNovember 7, 2024 | marketbeat.comSarepta Therapeutics, Inc. (SRPT) Q3 2024 Earnings Call TranscriptNovember 7, 2024 | seekingalpha.comSarepta Therapeutics Inc (SRPT) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ...November 7, 2024 | finance.yahoo.comSarepta Therapeutics Announces Third Quarter 2024 Financial Results and Recent Corporate DevelopmentsNovember 6, 2024 | businesswire.comAlphaCentric Advisors LLC Purchases 10,500 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)AlphaCentric Advisors LLC grew its position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 140.0% in the third quarter, according to its most recent filing with the SEC. The fund owned 18,000 shares of the biotechnology company's stock after acquiring an additional 10,500 shares durinNovember 5, 2024 | marketbeat.comEmerald Advisers LLC Has $1.04 Million Holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)Emerald Advisers LLC boosted its holdings in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 94.9% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 8,338 shares of the biNovember 4, 2024 | marketbeat.comGladstone Institutional Advisory LLC Has $10.40 Million Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)Gladstone Institutional Advisory LLC grew its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 47.7% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 83,300 shares of the biotechnology company'sNovember 1, 2024 | marketbeat.comPinnacle Associates Ltd. Boosts Stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)Pinnacle Associates Ltd. lifted its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 83.5% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 91,951 shares ofOctober 31, 2024 | marketbeat.comSarepta Therapeutics (SRPT) Scheduled to Post Quarterly Earnings on WednesdaySarepta Therapeutics (NASDAQ:SRPT) will be releasing earnings after the market closes on Wednesday, November 6, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=321230)October 30, 2024 | marketbeat.comSarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Acquired by abrdn plcabrdn plc increased its holdings in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 30.7% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 431,098 shares of the biotechnology company's stocOctober 30, 2024 | marketbeat.comChina Universal Asset Management Co. Ltd. Has $2.29 Million Stock Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)China Universal Asset Management Co. Ltd. boosted its stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 65.2% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 18,342 shares of the biotecOctober 29, 2024 | marketbeat.comSarepta Therapeutics, Inc. (SRPT): An Unstoppable Stock That Could Make You RicherOctober 27, 2024 | msn.comOptimistic Buy Rating for Sarepta Therapeutics Amid Strong International Demand and Collaborative PotentialOctober 25, 2024 | markets.businessinsider.comStrong International Sales and Strategic Growth Drive Buy Rating for Sarepta TherapeuticsOctober 25, 2024 | markets.businessinsider.comSarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Sold by Assenagon Asset Management S.A.Assenagon Asset Management S.A. lowered its holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 2.7% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 350,052 shares of the biotechnology company's stOctober 25, 2024 | marketbeat.comSarepta Therapeutics to Announce Third Quarter 2024 Financial ResultsOctober 23, 2024 | finance.yahoo.comZacks Research Analysts Raise Earnings Estimates for SRPTSarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) - Research analysts at Zacks Research boosted their Q2 2025 earnings per share (EPS) estimates for shares of Sarepta Therapeutics in a report released on Monday, October 21st. Zacks Research analyst S. Ganoria now forecasts that the biotechnoOctober 23, 2024 | marketbeat.comRBC Capital Remains a Buy on Sarepta Therapeutics (SRPT)October 23, 2024 | markets.businessinsider.comSarepta Therapeutics: Strong Buy Recommendation Driven by Expanding Elevidys Sales and Promising PipelineOctober 23, 2024 | markets.businessinsider.comJefferies Initiates Coverage of Sarepta Therapeutics (SRPT) with Buy RecommendationOctober 23, 2024 | msn.comSarepta a new buy at Jefferies on muscular dystrophy franchise, pipelineOctober 23, 2024 | seekingalpha.comRoyal Bank of Canada Reaffirms Outperform Rating for Sarepta Therapeutics (NASDAQ:SRPT)Royal Bank of Canada reaffirmed an "outperform" rating and issued a $182.00 price objective on shares of Sarepta Therapeutics in a research note on Monday.October 21, 2024 | marketbeat.com Get Sarepta Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SRPT and its competitors with MarketBeat's FREE daily newsletter. Email Address This Bull Market Indicator called NVDA at $116 (Ad)Every now and again we find an investment idea so incredible we can’t help but share. And today is one of those rare days… Except, today we won't be giving you insight on any one particular stock… But rather, insight on a revolutionary new stock picking indicator… In fact, within the last year, this indicator has become famous for a multitude of reasons… But one of the biggest was because of the buy signal it issued on October 18th, 2022. In fact, on that very day, it said to buy NVDA at $116.37… Anyone who did would be sitting on a tremendously large return today… But even if you missed the original buy signal from October, this incredible indicator issued 11 other buy signals while Nvidia made its epic run… All you have to do is follow this link here SRPT Media Mentions By Week SRPT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SRPT News Sentiment▼0.690.46▲Average Medical News Sentiment SRPT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SRPT Articles This Week▼1010▲SRPT Articles Average Week Get Sarepta Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SRPT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Jazz Pharmaceuticals News Today Ionis Pharmaceuticals News Today ACADIA Pharmaceuticals News Today Wave Life Sciences News Today Solid Biosciences News Today BioNTech News Today Teva Pharmaceutical Industries News Today BeiGene News Today Viatris News Today Summit Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SRPT) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sarepta Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sarepta Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SRPT Stock Alerts